ERBB2 and breast cancer: The ongoing phase 2 ACE-Breast-03 (NCT04829604) study is evaluating ARX788 activity and safety in patients with metastatic HER2-positive BC who are resistant to T-DM1, T-DXd, and/or tucatinib-containing regimens.